IONIS PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of Directors: Allene M. Diaz

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Allene M. Diaz”): 134,533,610 for, 3,812,549 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of directors to hold office until the 2028 Annual Meeting: The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 74,242,946 for, 2,494,224 against, 6,470 abstained, 59 not voted.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Description as filed by funds: Election of Directors: Joseph Klein, III

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Joseph Klein, III”): 127,135,692 for, 11,224,182 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of directors to hold office until the 2028 Annual Meeting: The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 72,632,027 for, 4,105,143 against, 6,470 abstained, 59 not voted.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Description as filed by funds: Election of Directors: Joseph Loscalzo

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Joseph Loscalzo”): 108,835,662 for, 29,465,062 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of directors to hold office until the 2028 Annual Meeting: The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 60,359,776 for, 16,377,393 against, 6,470 abstained, 59 not voted.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Description as filed by funds: Election of Directors: Michael Hayden

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael Hayden”): 133,250,556 for, 5,107,295 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of directors to hold office until the 2028 Annual Meeting: The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 74,242,942 for, 2,494,228 against, 6,470 abstained, 59 not voted.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Description as filed by funds: TO APPROVE AN AMENDMENT OF THE IONIS PHARMACEUTICALS, INC. 2011 EQUITY INCENTIVE PLAN TO INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER SUCH PLAN BY 4,000,000 SHARES TO AN AGGREGATE OF 42,500,000 SHARES.

IONIS PHARMACEUTICALS INC.’s own tally for this item (“3. Approval of an amendment of the Ionis Pharmaceuticals, Inc”): 108,160,711 for, 30,105,665 against — passed, per its Form 8-K filed June 10, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 61,670,833 for, 15,022,346 against, 6,470 abstained, 59 not voted.

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.

Description as filed by funds: To make an advisory vote on executive compensation.

IONIS PHARMACEUTICALS INC.’s own tally for this item (“2. An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of th”): 132,567,606 for, 5,738,006 against — passed, per its Form 8-K filed June 10, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 77 managers: 76,257,600 for, 428,399 against, 6,470 abstained, 59 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 322 managers: 98,523,303 for, 5,043,535 against, 1,443 abstained, 2,992 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE AUDIT COMMITTEE'S SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT AUDITORS FOR THE 2025 FISCAL YEAR.

IONIS PHARMACEUTICALS INC.’s own tally for this item (“4. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2025 fiscal year”): 144,587,537 for, 4,426,728 against — passed, per its Form 8-K filed June 10, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 76,320,257 for, 416,986 against, 6,470 abstained, 59 not voted.

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.